NCT01112033

Biliverdin Reductase A in Chronic Hepatitis C Virus Infection

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 113 (actual)
• Sponsor: Charles University, Czech Republic · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

In this project, the investigators aim to study the role of biliverdin reductase A (BLVRA) in HCV infected patients prior and during/after standard antiviral therapy in association with viral clearance, disease progression and treatment response and in comparison with healthy subjects.

Detailed description

1. To analyze biliverdin reductase (BLVRA) expression in the liver of HVC infected patients undergoing liver biopsy followed by standard antiviral treatment (peg-interferon plus ribavirin combination therapy) and patients with other forms of liver diseases undergoing liver biopsy as controls. 2. To analyze BLVRA expression in peripheral blood leukocytes (PBL) of therapeutically naïve HCV patients, during/after standard antiviral therapy and healthy controls. 3. To analyze BVLRA genetic polymorphisms both in HCV infected patients and healthy controls.

Conditions

• Hepatitis C, Chronic

Timeline

• Start date: 2010-06-01
• Primary completion: 2013-03-01
• Completion: 2013-06-01
• First posted: 2010-04-28
• Last updated: 2015-08-07

Locations

1 site across 1 country: Czechia